all report title image
  • Published On : Dec 2021
  • Code : CMI4827
  • Industry : Pharmaceutical
  • Pages : 192
  • Formats :

Muscle spasticity is a condition in which muscles contract, become stiff, or spasm involuntarily. The muscles contract making it difficult to stretch, walk, move, and talk. Spasticity is caused by damage to the areas of brain and spinal cord that are responsible for stretch reflexes and controlling muscle. This can be due to imbalance in the inhibitory and excitatory signals sent to the muscles. People with brain injury, spinal cord injury, multiple sclerosis, cerebral palsy, or stroke can have different degrees of spasticity.

The global spasticity market is estimated to be valued at US$ 4,167.6 million in 2021 and is expected to exhibit a CAGR of 8.9% during the forecast period (2021-2028).

Figure 1.Global Muscle Spasticity Market Share (%) in Terms of Value, By Drug Type, 2021

Muscle Spasticity  | Coherent Market Insights

Increasing prevalence of stroke, multiple sclerosis, and brain injury is expected to drive the market growth during the forecast period.

An increase in the prevalence of strokes, multiple sclerosis, and brain injuries is expected to drive the market growth during the forecast period. For instance, according to an article published in ‘International Journal of Neurorehabilitation’, in 2016, in America, approximately 795,000 people experience stroke each year, with around 610,000 of those being reported to be the first incidence of stroke. Research into spasticity prevalence in first stroke survivors indicates that up to 20-43% may experience some spasticity as a result of the injury.

CMI table icon

Muscle Spasticity Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,167.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.9% 2028 Value Projection: US$ $ 7,560.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, Others
  • By Route of Administration: Oral, Intramuscular, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc

Growth Drivers:
  • Increasing global healthcare expenditure
  • Launch of novel therapeutics
  • Advancements in the health care industry
Restraints & Challenges:
  • Lack of  availability of skilled professionals
  • Overall high cost of treatment
  • Inadequate reimbursement
  • Lack of disease awareness in emerging economies

Figure 2.Global Muscle Spasticity Market Share (%), By Distribution Channel, 2021

Muscle Spasticity  | Coherent Market Insights

Increasing research and development for developing effective therapies is expected to drive the market growth during the forecast period.

The increasing research and development of new and effective therapies for the treatment of muscle spasticity is expected to drive the market growth during the forecast period. For instance, in November 2021, Aditum Bio, the biotech investment firm for BioMedical Research, announced the formation of Motric Bio, a portfolio company developing a new therapy for spasticity associated with neurological injuries and disease. Current treatments target the central nervous system (CNS), with many causing cardiovascular and neurological side effects. Myosin-2 inhibitor molecule, which is to be developed by Motric Bio, has shown selectivity to fast skeletal myosin-2, with practically no inhibition of cardiac and smooth muscle myosins. This could lead to greater efficacy and fewer side effects than the current standard of care.

Global Muscle Spasticity Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has considerably impacted the muscle spasticity market. Most of the activities involved in the treatment of muscle spasticity have been either postponed or suspended. This prolonged suspension of activities has potentially exposed a lot of patients to the consequences of untreated spasticity.

COVID-19 has caused home confinement of patients, which may have triggered spasticity. For instance, according to an article published in ‘BioMed Research International journal’ on October 2021, both the number and the duration of oscillations (right leg), as well as the first swing excursion and relaxation index (left leg), decreased after home confinement, indicating increased spasticity.

Moreover, spasticity is a multifactorial problem, which is also influenced by psychological and behavioral aspects. COVID-19 has impacted the behavioral and psychological health of individuals (e.g., anxiety, fear of infection, and poorer sleep quality), which may have contributed to increased spasticity in people with multiple sclerosis.

Global Muscle Spasticity Market: Restraint

The major factors that hinder the growth of the global muscle spasticity market include lack of availability of skilled professionals, overall high cost of treatment, inadequate reimbursement, and lack of disease awareness in emerging economies.

Key Players

Major players operating in the global muscle spasticity market include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.

When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.

Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient’s needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.

Key features of the study:

  • This report provides an in-depth analysis of the global muscle spasticity market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global muscle spasticity market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market

Detailed Segmentation:

  • Global Muscle Spasticity Market, By Drug Type:
    • Baclofen
    • Botulinum Toxin
    • Diazepam
    • Dantrolene Sodium
    • Others
  • Global Muscle Spasticity Market, By Route of Administration:
    • Oral
    • Intramuscular
    • Others
  • Global Muscle Spasticity Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Muscle Spasticity Market, By Region:
    • North America
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Drug Type
        • Baclofen
        • Botulinum Toxin
        • Diazepam
        • Dantrolene Sodium
        • Others
      • Route of Administration
        • Oral
        • Intramuscular
        • Others
      • Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Ipsen Pharma
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Allergan
    • Acorda Therapeutics, Inc.
    • Merz Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Beximco Pharmaceuticals Ltd.
    • Johnson & Johnson Private Limited
    • Zydus Cadila
    • Hoffmann-La Roche Ltd.
    • Elite Pharmaceuticals Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global muscle spasticity market size is estimated to be valued at US$ 4,167.6 million in 2021 and is expected to exhibit a CAGR of 8.9% between 2021 and 2028.
Factors such as increasing global healthcare expenditure, launch of novel therapeutics, and advancements in the health care industry are expected to drive the growth of the market during forecast period.
Oral route of administration segment is expected to hold a major market share during the forecast period.
The major factors hampering the growth of the market include lack of availability of skilled professionals, overall high cost of treatment, inadequate reimbursement, and lack of disease awareness in emerging economies.
Major players operating in the market include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo